Blog - Generic Oncology

Blog

The Clinical Integration of Generic Oncology Medicines

The Science of Molecular Identity and Bioequivalence of Generic Oncology Medicines

Article Overview The news of a cancer diagnosis is a life-changing event that brings immediate emotional and practical challenges. Beyond the medical complexities of the disease, the cost of treatment often becomes a primary concern for patients and their families.…

Salma Abdel, Evidence-Based Medical Researcher
March 20, 2026

Blog, Generic oncolgoy medicines

How Generic Oncology Medicines Reduce the Financial Burden of Cancer Treatment

How Generic oncology medicines reduce the financial toxicity of cancer care

The diagnosis of cancer brings a sudden and immense weight to any family. While the primary goal is health and recovery, the conversation quickly turns to the high cost of treatment. In the medical world, the financial strain of caring…

Salma Abdel, Evidence-Based Medical Researcher
March 19, 2026

HER2-Negative (HER2-), HR+ Breast Cancer

CDK4/6 Pathway Dysregulation in Oncology: Molecular Drivers and Targeted Inhibitor Protocols

Mechanism-of-action-of-CDK4-6-inhibitors-Inhibition-of-G1-S-checkpoint | CDK4/6 Pathway

Protocol Summary Receiving an advanced oncology diagnosis necessitates an immediate transition from generalized anatomical staging to precise molecular and genomic profiling. In contemporary clinical oncology, the standard of care dictates that malignancies are evaluated and treated based on their specific,…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

HR+ Breast Cancer, HER2-Negative (HER2-), PIK3CA, AKT1, or PTEN Alteration

AKT Mutation Alterations in Oncology: Molecular Drivers and Targeted Inhibitor Protocols

Schematic-diagram-of-PI3K-Akt-mTOR-pathway-AKT Mutation

Educational Overview Receiving an advanced cancer diagnosis immediately necessitates a transition from generalized anatomical staging to precise molecular profiling. In modern oncology, the standard of care dictates that malignancies are treated based on their specific genetic drivers. Among the most…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

Blog, Acute Myeloid Leukemia Treatment, Precision Oncology

Clinical Guide to the FLT3 Mutation in Acute Myeloid Leukemia (AML)

Table of Content A primary diagnosis of Acute Myeloid Leukemia (AML) introduces patients and their families to a highly complex landscape of hematology, molecular biology, and genomic profiling. Modern precision oncology no longer relies solely on identifying the morphological type…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

Non-small Cell Lung Cancer Targeted Therapy, Blog

Clinical Guide to the BRAF Mutation and Targeted Therapy

Understanding your pathology report and genetic testing is the first step in precision oncology. If your tumor tissue has tested positive for a BRAF mutation, your medical team has identified the specific genetic driver responsible for your cancer’s growth. This…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

Blog, Non-small Cell Lung Cancer Targeted Therapy

ROS1 Gene Fusions in NSCLC: Targeted Therapies and Clinical Management

Receiving a cancer diagnosis immediately thrusts you into a complex world of medical terminology, cellular biology, and genetic testing. Today, oncology relies heavily on understanding the unique genetic blueprint of a tumor. Instead of categorizing cancer solely by where it…

Salma Abdel, Evidence-Based Medical Researcher
March 12, 2026

Blog

KRAS G12C Mutation in Advanced NSCLC: Targeted Therapies and Clinical Management

KRAS G12C Mutation involvement in non-small cell lung cancer. The Diagram shows the historical data of this mutation.

A cancer diagnosis often introduces a completely new vocabulary. You might hear your oncology team discuss genes, mutations, and targeted therapies. In modern oncology, treating cancer requires understanding the specific genetic blueprint of the tumor. One of the most significant…

Salma Abdel, Evidence-Based Medical Researcher
March 12, 2026

Blog

NSCLC Targeted Therapies: Biomarker Profiling and Precision Oncology Protocols

How Receptor Tyrosine kinase inhibitor works in non-small cell lung cancer

Introduction: The Shift to Precision Medicine Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for roughly 80% to 85% of all lung cancer diagnoses. For decades, the standard approach to treating NSCLC relied heavily…

Salma Abdel, Evidence-Based Medical Researcher
March 12, 2026

Blog, HR+ Breast Cancer

PIK3CA Mutations in HR+ Breast Cancer: Targeted Therapies and Metabolic Management

If you have been told you have a PIK3CA mutation, you are likely dealing with Hormone Receptor-positive (HR+), HER2-negative metastatic breast cancer. This blog is designed to pull back the curtain on the science, explain the research, and help you…

Salma Abdel, Evidence-Based Medical Researcher
March 1, 2026

Trending now